Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act(PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; Pharmacy benefit managers (PBM) reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Congressionally Directed Medical Research Program (malaria); Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to pharmaceutical intellectual property.
Issues related to tax reform. Research and Development tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.
Issues related to supply chain and tariffs.
H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.